BioSpace News Archive

Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim analysis expected in mid-2021

March kicks-off the company’s donation match through Uplifting Athletes’ Reps for Rare Diseases program to further research for new therapies

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of ORLADEYO™

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the full year ended Dec. 31, 2020 and provided a corporate update.

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar at 11 a.m. ET on March 4 that will describe how primary hepatocytes are being used to screen small molecule drugs for activity against the Plasmodium parasites that cause malaria.

Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance.

Fusion Robotics LLC, a spinal robotics and navigation company today announced receiving 510(k) clearance to market their 3D imaging compatible navigation and robotic targeting system for spine surgery in the U.S. market.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a virtual presentation during the Cowen 41st Annual Health Care Conference taking place March 1-4, 2021.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 1,562,500 common shares of Edesa, at a price to the public of $6.40 per share, less underwriting discounts and commissions.